Skip to Main Content

Paper Details

Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.
Sci Signal
15
2018
AML, AML cells, JMML, JMML and AML cells, MAPK, PTPN11, PTPN11-mutant JMML, PTPN11-mutant JMML and AML cells, PTPN11-mutant leukemia, PTPN11-mutant leukemias, TNK2, acute myeloid leukemia, bone marrow cells, cultured human cell, dasatinib, human, juvenile myelomonocytic leukemia, malignancies, mice, mitogen-activated protein kinase, mutant PTPN11, nonreceptor tyrosine/serine/threonine kinase, patient, protein tyrosine phosphatase PTPN11, serine, threonine, tyrosine
Animals, Child, Dasatinib, Humans, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Juvenile, Male, Mice, Prognosis, Protein Kinase Inhibitors, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Protein-Tyrosine Kinases, Signal Transduction, Survival Rate, Synthetic Lethal Mutations, Tumor Stem Cell Assay
Author NameAffiliation
Chelsea JenkinsOregon Health & Science University
Chelsea JenkinsKnight Cancer Institute, Oregon Health & Science University
Samuel B LutyOregon Health & Science University
Samuel B LutyKnight Cancer Institute, Oregon Health & Science University
Julia E MaxsonKnight Cancer Institute, Oregon Health & Science University
Julia E MaxsonOregon Health & Science University
Christopher A EideKnight Cancer Institute, Oregon Health & Science University
Melissa L AbelOregon Health & Science University
Melissa L AbelKnight Cancer Institute, Oregon Health & Science University
Corinne TogiaiOregon Health & Science University
Corinne TogiaiKnight Cancer Institute, Oregon Health & Science University
Eneida R NemecekKnight Cancer Institute, Oregon Health & Science University
Eneida R NemecekOregon Health & Science University
Daniel BottomlyOregon Clinical and Translational Research Institute
Daniel BottomlyDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University
Shannon K McWeeneyKnight Cancer Institute, Oregon Health & Science University
Shannon K McWeeneyOregon Clinical and Translational Research Institute
Shannon K McWeeneyDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University
Beth WilmotKnight Cancer Institute, Oregon Health & Science University
Beth WilmotOregon Clinical and Translational Research Institute
Beth WilmotDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University
Marc M LoriauxKnight Cancer Institute, Oregon Health & Science University
Marc M LoriauxOregon Health & Science University
Bill H ChangKnight Cancer Institute, Oregon Health & Science University
Bill H ChangOregon Health & Science University
Jeffrey W TynerOregon Health & Science University
Jeffrey W TynerKnight Cancer Institute, Oregon Health & Science University
  • 1 - 27

Datasets

Release 1.2